drugset / Trial / NCT05493111
A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety of topical ophthalmic 0.003% AR-15512 compared to its vehicle dosed twice daily (BID) in subjects with dry eye disease (DED) for 12 months.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2024-02-28
- Completion
- 2024-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acoltremon | Small molecule | 0.003 % | Topical |